Brain Metastases Strike 1 in 3 HER2-Positive Breast Cancer Patients Within 5 Years

Brain metastases represent one of the most serious complications for patients with HER2-positive metastatic breast cancer, and new real-world data are sharpening the picture of just how frequently and how early this occurs. For health-conscious individuals and caregivers navigating a breast cancer diagnosis, understanding these risks and the current state of treatment options is critically important.

A real-world analysis of metastatic breast cancer in the United States found that patients with hormone receptor-negative, HER2-positive disease had the highest brain metastasis incidence of any molecular subtype — 13.1% at the start of first-line therapy. Within five years of a metastatic diagnosis, that figure climbed to 34%. Prevalence nearly tripled between first- and second-line treatment, rising from 11.2% to 31.2%, underscoring how aggressively this cancer can spread to the central nervous system.

Despite these alarming rates, oncology guidelines from ASCO stop short of recommending routine brain MRI surveillance for asymptomatic patients. The evidence that detecting brain metastases earlier actually improves survival remains insufficient, and earlier detection can lead patients toward more invasive interventions — including stereotactic radiosurgery or neurosurgery — that may cause more harm than good if systemic therapy is already working.

A key development offering cautious optimism is trastuzumab deruxtecan (T-DXd, marketed as Enhertu), an antibody-drug conjugate shown to have meaningful activity inside the brain. Experts note that for patients with small, asymptomatic brain metastases already on T-DXd, aggressive local intervention may be unnecessary and potentially harmful.

The broader clinical implication is a call for well-designed screening and prevention trials, particularly timed around treatment transitions when brain metastasis risk surges. Until clearer survival data exist, individualized shared decision-making between patients and oncologists remains the recommended approach.